Gliknik, Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders. Its Immunomodulator Platform involves in off-the-shelf peptide drugs that increase CD4, CD8, and antibody immune responses against cancer; Stradomer Platform produces drugs designed to mimic the eficacy of pooled human intravenous immunoglobulin; and Stradobody Platform produces compounds that are similar to moncolonal antibodies for tumor cell killing. The company was founded in 2007 and is based in Baltimore, Maryland.
Funding Rounds (8) - $48.4MUpdate
Board Members and Advisors (4)Update
801 W. Baltimore Street
Baltimore, MD 21201